Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Tango Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOSTON, SEPT. 03, 2026 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX) (TANGO THERAPEUTICS OR THE COMPANY) TODAY ANNOUNCED THAT, EFFECTIVE SEPTEMBER 1, 2026, THE COMPENSATION COMMITTEE OF TANGO THERAPEUTICS' BOARD OF DIRECTORS GRANTED A NON-QUALIFIED STOCK OPTION TO PURCHASE 146,500 SHARES OF ITS COMMON STOCK AND 40,000 RESTRICTED STOCK UNITS (RSUS) TO A NEW EMPLOYEE UNDER TANGO THERAPEUTICS' 2023 INDUCEMENT PLAN.

TANGO THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BOSTON, SEPT. 01, 2026 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX) (TANGO THERAPEUTICS OR THE COMPANY) TODAY ANNOUNCED THAT MEMBERS OF THE MANAGEMENT TEAM ARE SCHEDULED TO PARTICIPATE IN A FIRESIDE CHAT AT THE 2026 CANTOR GLOBAL HEALTHCARE CONFERENCE ON WEDNESDAY, SEPTEMBER 9, 2026 AT 8:35 AM EDT.

TANGO THERAPEUTICS TO PARTICIPATE IN THE 2026 CANTOR GLOBAL HEALTHCARE CONFERENCE

BOSTON, AUG. 06, 2026 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING AND DELIVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, TODAY ANNOUNCED THAT DR. BARBARA WEBER, THE EXECUTIVE CHAIRMAN OF THE BOARD OF DIRECTORS OF TANGO THERAPEUTICS, WILL BE STEPPING DOWN IN CONNECTION WITH OTHER PURSUITS.

TANGO THERAPEUTICS ANNOUNCES EXECUTIVE CHAIR TRANSITION

BOSTON, JUNE 22, 2026 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING AND DELIVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, TODAY ANNOUNCED THE APPOINTMENT OF ROBERT AZELBY TO ITS BOARD OF DIRECTORS. MR. AZELBY BRINGS MORE THAN THREE DECADES OF LEADERSHIP EXPERIENCE ACROSS THE BIOPHARMACEUTICAL INDUSTRY, INCLUDING DEEP EXPERTISE IN ONCOLOGY COMMERCIALIZATION, CORPORATE STRATEGY, COMPANY BUILDING AND BOARD GOVERNANCE. HIS APPOINTMENT COMES AS TANGO ADVANCES VOPIMETOSTAT, ITS INVESTIGATIONAL PRMT5 INHIBITOR WITH FIRST- AND BEST-IN-CLASS POTENTIAL, TOWARD POTENTIAL LATE-STAGE DEVELOPMENT FOR PATIENTS WITH PANCREATIC CANCER.

TANGO THERAPEUTICS APPOINTS ROBERT AZELBY TO BOARD OF DIRECTORS

BOSTON, JUNE 09, 2026 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (TANGO) (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING AND DELIVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, ANNOUNCED TODAY THE PRICING OF AN UNDERWRITTEN OFFERING OF 18,166,667 SHARES OF ITS COMMON STOCK AND PRE-FUNDED WARRANTS TO PURCHASE UP TO 1,833,395 SHARES OF ITS COMMON STOCK (THE OFFERING). THE OFFERING PRICE OF EACH SHARE OF COMMON STOCK IS $30.00. THE OFFERING PRICE OF EACH PRE-FUNDED WARRANT IS $29.999, WHICH REPRESENTS THE PER SHARE OFFERING PRICE FOR THE COMMON STOCK LESS THE $0.001 PER SHARE EXERCISE PRICE FOR SUCH PRE-FUNDED WARRANT. THE GROSS PROCEEDS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING-RELATED EXPENSES, ARE EXPECTED TO BE APPROXIMATELY $600 MILLION. ALL OF THE SHARES AND PRE-FUNDED WARRANTS IN THE OFFERING ARE TO BE SOLD BY TANGO. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT JUNE 11, 2026, SUBJECT TO CUSTOMARY CLOSING CONDITIONS. IN ADDITION, TANGO HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 3,000,009 SHARES OF COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNT.

TANGO THERAPEUTICS ANNOUNCES PRICING OF $600 MILLION UPSIZED PUBLIC OFFERING

BOSTON, JUNE 08, 2026 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (TANGO) (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING AND DELIVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, ANNOUNCED TODAY THE LAUNCH OF AN UNDERWRITTEN PUBLIC OFFERING (THE OFFERING) OF $500 MILLION OF ITS COMMON STOCK. ALL SHARES OF COMMON STOCK TO BE SOLD IN THE OFFERING WILL BE OFFERED BY TANGO. TANGO ALSO INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $75,000,000 OF SHARES OF ITS COMMON STOCK OFFERED IN THE OFFERING UNDER THE SAME TERMS AND CONDITIONS. THE OFFERING IS SUBJECT TO MARKET CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR THE ACTUAL SIZE OR TERMS OF THE OFFERING.

TANGO THERAPEUTICS ANNOUNCES PROPOSED $500 MILLION PUBLIC OFFERING

INITIAL DATA FROM ONGOING PHASE 1/2 TRIAL IN PATIENTS WITH SECOND AND THIRD LINE PDAC TREATED WITH VOPIMETOSTAT AND DARAXONRASIB SHOWED 6-MONTH PFS RATE OF 90% (MEDIAN PFS NOT YET REACHED) SUGGESTING DURABILITY OF CLINICAL BENEFIT VOPIMETOSTAT COMBINATIONS WITH REVOLUTION MEDICINES' RAS(ON) INHIBITORS DARAXONRASIB OR ZOLDONRASIB WERE GENERALLY WELL-TOLERATED DATA SUPPORT RAPID ADVANCEMENT OF VOPIMETOSTAT PLUS DARAXONRASIB COMBINATION INTO PHASE 3 DEVELOPMENT IN FIRST-LINE MTAP DELETED PANCREATIC CANCER CONFERENCE CALL TODAY, JUNE 8, 2026, AT 8:00AM ET BOSTON, JUNE 08, 2026 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING AND DELIVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, TODAY ANNOUNCED POSITIVE INITIAL DATA FROM ITS ONGOING PHASE 1/2 STUDY OF VOPIMETOSTAT, AN INVESTIGATIONAL PRMT5 INHIBITOR WITH FIRST- AND BEST-IN-CLASS POTENTIAL, IN COMBINATION WITH REVOLUTION MEDICINES' RAS(ON) INHIBITORS IN PATIENTS WITH MTAP-DELETED AND RAS-MUTANT METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC). IN THE FIRST REPORTED DATA FROM THE CLINICAL COMBINATIONS OF OUR PRMT5 INHIBITOR VOPIMETOSTAT AND RAS(ON) INHIBITORS, WE SAW EXTREMELY ENCOURAGING EARLY RESULTS, WITH 92% OF PATIENTS WITH PDAC IN THE VOPIMETOSTAT PLUS DARAXONRASIB ARM ACHIEVING AN OBJECTIVE RESPONSE, SUPPORTING THE PRECLINICAL DATA SHOWING SYNERGISTIC ACTIVITY OF PRMT5 + RAS INHIBITION, SAID MALTE PETERS, MD, CHIEF EXECUTIVE OFFICER OF TANGO THERAPEUTICS.

TANGO THERAPEUTICS ANNOUNCES COMBINATION OF VOPIMETOSTAT AND DARAXONRASIB DEMONSTRATED 92% OBJECTIVE RESPONSE RATE IN PANCREATIC CANCER

BOSTON, JUNE 05, 2026 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), TODAY ANNOUNCED THAT, EFFECTIVE JUNE 1, 2026, THE COMPENSATION COMMITTEE OF TANGO THERAPEUTICS' BOARD OF DIRECTORS GRANTED A NON-QUALIFIED STOCK OPTION TO PURCHASE 170,000 SHARES OF ITS COMMON STOCK AND 40,000 RESTRICTED STOCK UNITS (RSUS) TO A NEW EMPLOYEE UNDER TANGO THERAPEUTICS' 2023 INDUCEMENT PLAN.

FIRST CLINICAL DATA FROM PRMT5/RAS(ON) COMBINATION TRIAL TO BE PRE SENTED IN 2026 CASH POSITION OF $380 MILLION AS OF MARCH 31, 2026, WITH RUNWAY INTO 2028 BEYOND ANTICIPATED KEY DATA INFLECTION POINTS BOSTON, MAY 13, 2026 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING AND DELIVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED BUSINESS HIGHLIGHTS. WE CONTINUE TO WORK DILIGENTLY TO ADVANCE VOPIMETOSTAT TOWARDS PIVOTAL DEVELOPMENT IN PANCREATIC CANCER AND REMAIN HIGHLY ENCOURAGED BY THE POTENTIAL OF THE ONGOING STUDY OF VOPIMETOSTAT IN COMBINATION WITH RAS(ON) INHIBITORS, SAID MALTE PETERS, M.D.

TANGO THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS

BOSTON, MAY 04, 2026 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), TODAY ANNOUNCED THAT EFFECTIVE MAY 1, 2026, THE COMPENSATION COMMITTEE OF TANGO THERAPEUTICS' BOARD OF DIRECTORS GRANTED (I) A NON-QUALIFIED STOCK OPTION TO PURCHASE AN AGGREGATE OF 240,000 SHARES OF ITS COMMON STOCK AND 40,000 RESTRICTED STOCK UNITS (RSUS) TO MATTHEW GALL, THE COMPANY'S CHIEF FINANCIAL OFFICER AND (II) A NON-QUALIFIED STOCK OPTION TO PURCHASE AN AGGREGATE OF 199,650 SHARES OF ITS COMMON STOCK AND 33,250 RSUS TO A NEW EMPLOYEE, UNDER TANGO THERAPEUTICS' 2023 INDUCEMENT PLAN.

Tango Therapeutics, Inc.

TNGX

Price

Financial Reports

No items found.

Press Releases

Tango Therapeutics, Inc.

TNGX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

TNGX